Renaissance Capital logo

AXON News

Ending endocrine disorders: Myovant Sciences prices upsized IPO above the range at $15

MYOV

Myovant Sciences, a newly-formed biotech developing an acquired therapy for endocrine disorders, raised $218 million by offering 14.5 million shares at $15, the high end of the range of $12 to $15. Myovant Sciences plans to list on the NYSE under the symbol MYOV. Citi, Cowen & Company, Evercore ISI and Barclays acted as lead managers on the deal. Parent company Roivant...read more

Alzheimer's biotech AC Immune files for a $50 million IPO

ACIU

AC Immune, a Swiss biotech developing therapies for Alzheimer's disease, filed on Tuesday with the SEC to raise up to $50 million in an initial public offering. The Lausanne, Switzerland-based company was founded in 2003 and booked $39 million in sales for the 12 months ended March 31, 2016. It plans to list on the Nasdaq under the symbol ACIU. AC Immune filed confidentially...read more

Alzheimer's biotech vTv Therapeutics sets terms for $125 million IPO

vTv Therapeutics, a biotech developing treatments for Alzheimer's disease and type 2 diabetes, announced terms for its IPO on Monday. The High Point, NC-based company plans to raise $125 million by offering 7.8 million shares at a price range of $15 to $17. At the midpoint of the proposed range, vTv Therapeutics would command a basic market value of $525 million. The last...read more

US IPO Weekly Recap: Wingstop unstoppable while massive biotech pops 99% then drops

WING

Five IPOs raised $565 million this past week. The deals average +30% from the offer price, while none broke issue and most priced above the midpoint of the range.  78 companies have gone public in the US this year,...read more